Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 322.47M | 334.29M | 397.99M | 365.88M | 260.09M | 119.09M |
Gross Profit | 182.51M | 182.30M | 155.11M | 248.78M | 178.54M | 67.20M |
EBITDA | -7.82M | 10.34M | -53.56M | 80.75M | -22.00M | -2.81M |
Net Income | -38.52M | -29.10M | -100.12M | 44.22M | -375.11M | -29.18M |
Balance Sheet | ||||||
Total Assets | 673.82M | 685.68M | 929.11M | 1.01B | 1.22B | 222.84M |
Cash, Cash Equivalents and Short-Term Investments | 373.03M | 370.06M | 523.02M | 568.20M | 901.89M | 9.49M |
Total Debt | 567.69M | 568.16M | 752.29M | 751.79M | 746.41M | 216.54M |
Total Liabilities | 627.76M | 633.88M | 869.72M | 837.43M | 916.51M | 252.79M |
Stockholders Equity | 46.06M | 51.80M | 59.39M | 171.48M | 302.30M | -29.96M |
Cash Flow | ||||||
Free Cash Flow | 29.85M | 9.34M | 8.70M | -123.99M | -43.98M | -16.25M |
Operating Cash Flow | 35.98M | 16.13M | 21.75M | -106.60M | -28.36M | -12.44M |
Investing Cash Flow | -6.14M | -6.79M | -31.51M | -18.87M | -37.73M | -3.82M |
Financing Cash Flow | -99.97M | -158.34M | -37.45M | -205.24M | 959.03M | 18.27M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $608.82M | 6.14 | 13.68% | 2.09% | -11.79% | ― | |
65 Neutral | $234.69M | 21.02 | 10.98% | ― | -5.04% | -22.01% | |
63 Neutral | $20.50B | 14.76 | -2.72% | 3.09% | 1.90% | -4.74% | |
58 Neutral | $1.10B | 17.42 | 4.12% | 2.56% | -2.92% | -43.06% | |
55 Neutral | $254.92M | ― | -26.54% | ― | -15.33% | 75.52% | |
52 Neutral | $589.26M | 5.74 | -23.99% | ― | -4.39% | -326.42% | |
46 Neutral | $3.82B | 40.12 | -9.98% | ― | -3.68% | -631.67% |
On September 4, 2025, The Beauty Health Company, along with its domestic and foreign subsidiaries, entered into a Supplemental Indenture with U.S. Bank Trust Company to modify an existing indenture related to its 7.95% Convertible Senior Notes due 2028. This modification includes securing the notes with a first-priority guarantee by new foreign subsidiaries and addressing certain ambiguities in the original indenture, potentially strengthening the company’s financial structure and enhancing investor confidence.
On July 31, 2025, The Beauty Health Company filed a Certificate of Correction to amend an error in its corporate governance documents, allowing directors to be removed with or without cause by a majority vote. Additionally, the Board appointed Stephen Fanning as Chairman of the Nominating and Corporate Governance Committee, reflecting a strategic move in its leadership structure.
On June 12, 2025, The Beauty Health Company held its annual stockholders meeting virtually, where 78.40% of the shares were represented, establishing a quorum. During the meeting, seven directors were elected for a one-year term, Deloitte & Touche LLP was ratified as the independent auditor, and the compensation for named executive officers was approved on a non-binding basis.